섹시스타킹쿵쾅닷컴druwamall.com섹스숍우리넷opqrㆃㆄ
페이지 정보
작성자 츠쇼븨허42 작성일20-04-07 15:28 조회85회 댓글0건본문
[A0812] 쌔끈한 란제리 촬영현장 / 레드폭스 코스프레 섹시속옷 스타킹 게시자: 레드폭스코스프레 6시간 전 2분 39초 조회수 11회
CAMBRIDGE, MASS.--( / ) July 24, 2014 -- Today Biogen Idec (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe.
“PLEGRIDY offers people living with MS an interferon with compelling efficacy that requires considerably fewer injections than other platform therapies," said George A. Scangos, Ph.D., chief executive officer at Biogen Idec. “The approval of PLEGRIDY demonstrates our commitment to improving the lives of patients by providing innovative therapies that meet their individual needs, including flexibility in managing their disease.”
PLEGRIDY, the only pegylated interferon approved for use in RRMS, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression.
The EC approval of PLEGRIDY is based on results from one of the largest pivotal studies of a beta interferon conducted, ADVANCE1, which involved more than 1,500 patients with relapsing forms of MS.
In the ADVANCE clinical trial, PLEGRIDY, dosed once every two weeks, significantly reduced annualized relapse rate (ARR) at one year by 36 percent compared to placebo (p=0.0007).
PLEGRIDY reduced the risk of sustained disability progression confirmed at twelve weeks by 38 percent (p=0.0383) and at twenty four weeks by 54 percent (p=0.0069, post-hoc analysis). In addition, the number of gadolinium-enhancing [Gd+] lesions was significantly reduced by 86 percent (p<0.0001) compared to placebo.
Results over two years of ADVANCE confirm that its robust efficacy was maintained beyond the placebo-controlled first year of the study.
“The safety and efficacy that PLEGRIDY has demonstrated, combined with its less frequent dosing schedule offers MS patients an option to put their treatment in the background for longer stretches of time,” said Professor Bernd C. Kieseier, M.D., Heinrich-Heine Universitat, Dusseldorf.
The safety and tolerability profile of peginterferon beta-1a observed in ADVANCE1 was consistent with that of established MS interferon therapies. The most commonly reported adverse drug reactions with peginterferon beta-1a treatment (incidence ≥10% and at least 2% more frequent on peginterferon beta-1a than on placebo) were injection site reaction, flu-like illness, fever, headache, muscle pain, chills, injection site pain, weakness, injection site itching, and joint pain.1
PLEGRIDY is the fifth therapy to be offered by Biogen Idec to people living with MS, expanding on a portfolio that addresses individual patient needs.
For more information on PLEGRIDY, visit biogenidec.com. Additional resources on PLEGRIDY are available for the media upon request.
About PLEGRIDY™
PLEGRIDY is a subcutaneous injectable therapy for relapsing-remitting multiple sclerosis (RRMS), in which interferon beta-1a is pegylated to extend its half-life to permit a less frequent dosing schedule. PLEGRIDY is a member of the interferon class of treatments for MS.
According to the EU Summary of Product Characteristics (SmPC), the recommended starting dose of PLEGRIDY is 63 micrograms at dose 1, increasing to 94 micrograms at dose 2, reaching the full dose of 125 micrograms by dose 3 and continuing with the full dose (125 micrograms) every 2 weeks thereafter.
The safety and tolerability profile of PLEGRIDY observed in ADVANCE1 was consistent with that of established MS interferon therapies. PLEGRIDY should be administered with caution to patients with previous depressive disorders, seizures, severe hepatic impairment and severe renal impairment. Cytopenias, including rare severe neutropenia and thrombocytopenia, have been observed in patients treated with PLEGRIDY. The following have been reported with interferon beta medicinal products including PLEGRIDY: Elevations in hepatic enzymes, serious hypersensitivity reactions, injection site reactions with subcutaneous administration, including injection site necrosis, and worsening of cardiac disease.
In addition, the EU SmPC indicates that the use of interferon beta products is associated with cases of nephrotic syndrome, thrombotic microangiopathy manifested as thrombotic thrombocytopenic purpura (TTP) or haemolytic uraemic syndrome (HUS), hyper and hypothyroidism, hepatitis, autoimmune hepatitis, rare cases of severe hepatic failure, and decreased peripheral blood counts, including rare pancytopenia.
About Pegylation
Pegylation prolongs the circulation time of the molecule in the body by increasing its size, thus enabling a longer half-life, stabilizing the molecule by improving its solubility and shielding the molecule from enzymes in the body that try to break it down into smaller particles.3 Pegylation is a well-established scientific process that has been used for more than 20 years.2,3
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system, which is made up of the brain, spinal cord and optic nerves. Symptoms may be mild or severe, ranging from numbness in the limbs to paralysis or loss of vision. The progression, severity and specific symptoms of MS are unpredictable and vary from one person to another. MS affects more than 2.3 million people worldwide,4 with more than 600,000 sufferers in the European Union.5 Relapsing-remitting MS (RRMS) is the most common form of MS accounting for 85 percent of cases. It is characterized by clearly defined acute attacks with full recovery or with residual deficit upon recovery.6
About Biogen Idec
Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the Company, please visit
Safe Harbor
This press release contains forward-looking statements, including statements about the potential benefits of PLEGRIDY and the expected timing of commercial launch in the EU. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of success in commercialization of PLEGRIDY, intense competition in the MS market, unexpected hurdles or difficulties in launching PLEGRIDY, difficulties obtaining or changes in the availability of reimbursement for PLEGRIDY, problems with our manufacturing processes for PLEGRIDY, the occurrence of adverse safety events, and the other risks and uncertainties that are described in the Risk Factors section of our most recent annual or quarterly report and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements speak only as of the date of this press release and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
References
1 Calabresi PA et al. Peginterferon Beta-1a Provides Improvements in Clinical and Radiological Disease Activity in Relapsing-Remitting Multiple Sclerosis: Year 1 Findings from the Phase 3 ADVANCE. Poster presented at 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, 2013.
2 Bailon P and Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6: 1-16, 2009.
3 Reuss R. PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics: Targets and Therapy 7: 131-139, 2013. Available at Accessed March 2014.
4 Multiple Sclerosis International Federation, Atlas of MS 2013. Epidemiology of MS. Page 8. Date Accessed: Mar. 17, 2014.
5 Multiple Sclerosis International Federation. Atlas of MS 2013. Epidemiology of MS. Date Accessed: Mar. 17, 2014.
6 NMSS. Relapsing-Remitting MS. Date accessed: Mar. 17, 2014.Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
조또TV LONDON--(/ ) March 14, 2017 -- Urgent action is required 콕이오 LONDON--(limit the global fallout from 섹시산타복 러브젤페페 rising obesity levels, according to a report published today by Aetna International, one 브라보카지노 of the world’s 섹시산타복 코리아카지노 leading health insurance providers.
Aetna International combined data from 사정지연 the World Health Organisation (WHO), the United Nations, governments and the global food industry to 꽁딸시즌2 Aetnaa comprehensive analysis which presents a 섹시산타복 true picture of global obesity. The report, “Globesity: Tackling the world’s obesity pandemic”, calls upon governments, food producers, retailers, employers and insurance companies to combine their efforts to tackle the obesity crisis.
Richard di Benedetto, President 섹시산타복 스포츠토토분석 of Aetna International, said: “The rise 오르가즘젤 in obesity rates make it clear; there needs to be a shift in the narrative around diet and healthy 섹시산타복 living. We must work together to combine our knowledge and expertise in order to curb the rise of 펑키 Richard
The 파워볼필승법 WHO statistics show that obesity 섹시산타복 rates have 누나곰닷컴 The than doubled since 1980, with 13 percent of adults 섹시산타복 성인용품당일배송 worldwide classified as obese and nearly 40 섹시산타복 스포츠토토베트맨 percent as overweight. The report findings show that these 성인용품샾 numbers will rise further if urgent, collaborative 딸통령 Thetargeted action is not taken.
The 소리넷 Theconcludes that the only way to tackle globesity is through a 자선냄비 Theformed holistic approach 섹시산타복 188bet combining health incentives, taxes and education BET365 programs. It has been W88 proven that one of the 철수넷 Theeffective means of reducing obesity is providing clear information 섹시산타복 벳이스트 about the direct correlation between nutrition, weight gain and non-communicable diseases.
“Aetna is 섹시산타복 committed to being part of the solution to globesity 섹코 “Aetnato creating a stronger, 야빵 “Aetnaglobal community. We are working towards establishing a think-tank 죽음란죄 with the sole purpose of finding solutions to 섹시산타복 the problems presented by worldwide obesity”, concludes Mr di Benedetto.
About 라이브맨더빙 섹시산타복 라이브맨더빙 밤왕 About 야구픽 International 축구픽 섹시산타복 축구픽
Aetna International is committed to helping create a stronger, healthier global community by delivering comprehensive health care benefits and population health solutions worldwide. One of the largest 섹시산타복 여자성기구 providers of international private medical insurance, Aetna 네토닷컴 Aetnaserves more than 700,000 members worldwide, including expatriates, 방자전 Aetnanationals and business travellers. Its global benefits include medical, 섹시산타복 오카모토리얼핏 dental, vision and emergency assistance and, in some regions, life and disability. Aetna International also offers customised technological and health management solutions for health AV쇼미 Aetnasystems, government entities 섹시산타복 프로농구감독 and large employers to improve people’s health, enhance quality of care and contain costs. For more information, see
보토리넷 About 동행복권파워볼당첨 섹시산타복 동행복권파워볼당첨 Aetna 섹시산타복 사가미익스트림
Aetna is one of the nation‘s leading diversified health care benefits companies, serving an estimated 46.7 million people with information and resources to help them make better 섹시산타복 informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed 야킹 Aetnainsurance products and related services, including medical, pharmacy, dental, behavioral health, 섹시산타복 파워키노사다리 group life and disability plans, and medical management capabilities, Medicaid health care 파워키노사다리분석 management 늑대비디오 Aetnaworkers’ compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly 밤의신 Aetnahealth plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, see and learn about how Aetna is helping to build a healthier world. @AetnaNews
미소넷 Viewsource version on 섹시산타복 먹튀수사대 businesswire.com:Korea Newswire 먹튀폴리스믿을만 distributes your news across every media 스킨콘돔 channels through the industry’s boomboom Viewpress release distribution network
댓글목록
등록된 댓글이 없습니다.